Skip to content
Head to head

Kardigan vs Vertex Pharmaceuticals

Side-by-side on the measures that matter, with a plain-English read. Full detail: KARD · VRTX

Updated 8 minutes ago

1-year performance, rebased to 100

KARD -47.5%VRTX +14.0%
Vertex Pharmaceuticals edges it on the scoreable measures. Vertex Pharmaceuticals has the highest Quant Rating (68); Vertex Pharmaceuticals earns the most per share.
KARDVRTX
Snapshot
Sector--Biotechnology
Last price11.54515.02
Change today-7.83%-1.08%
1-year return--+22.0%
Market cap$1.08B$130.58B
52-week range11.49 – 27.00412.27 – 568.67
Valuation
P/E (TTM)-3.7633.14
P/E percentile, own 5-yr range83rd99th
P/B1.896.25
Dividend yield0.00%0.00%
Profitability & growth
EPS (TTM)-2.1915.32
Net profit (TTM)$-204.88M$3.88B
Revenue (TTM)--$12.95B
Provider revenue period date2026-06-292026-09-29
Revenue growth (YoY)--+11.8%
Gross margin--85.5%
Operating margin--33.1%
Net margin--30.7%
Free cash flow (TTM)--$3.20B
Provider cash-flow period date2026-06-292026-09-29
Ownership & sentiment
Institutional ownership83.5%96.8%
Insider activity (12mo)16 buy / 0 sell28 buy / 22 sell
Short interest (% of float)6.1%1.9%
Analyst consensus100% buy (8)95% buy / 5% hold (21)
Analyst price target$41 (+253%)$624 (+21%)
StockVane view
StockVane Quant RatingC (0)C (68)
Company
Employees3806,400
Founded20231989

▲ marks the more favourable stock(s) on measures with a clear direction (lower P/E, higher yield, higher Quant Rating, better 1-year return). Analyst consensus counts each covering institution once, at its most recent rating. Not a recommendation. Quant Rating method: Data & Methodology.